Multiple sclerosis (MS) is a genetically complex disease that shares a substantial proportion of risk loci with other autoimmune diseases. 1 Along these lines, ANKRD55, originally implicated in rheumatoid arthritis, was recently reported as a potential novel MS risk gene (rs6859219, p=1.9×10 −7 ). 2 Here, we comprehensively validated this effect in independent datasets comprising 8846 newly genotyped subjects from Germany and France as well as 5003 subjects from two genome-wide association studies (GWAS). Upon meta-analysis of all available data (19 686 subjects), ANKRD55 rs6859219 now shows compelling evidence for association with MS at genome-wide significance (OR=1.19, p=3.1×10 −11 ). Our study adds ANKRD55 to the list of established MS risk loci and extends previous evidence suggesting an overlapping genetic foundation across autoimmune diseases.
Ankyrin repeats are abundant in a large number of different proteins in humans and mediate protein-protein interactions. DNA-sequence variants in ankyrin repeat domain-containing proteins have been linked to a wide range of diseases; for example, KRIT1 mutations causative for cerebral cavernous malformations, 3 NOTCH3 mutations in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, and RFXANK mutations in the bare lymphocyte syndrome.
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ANKRD55 (located on chromosome 5q11.2) encodes the 'ankyrin repeat domaincontaining protein 55' the function of which is currently unknown. Single nucleotide polymorphism rs6859219 in ANKRD55 was implicated in a recent GWAS meta-analysis on rheumatoid arthritis. 5 Furthermore, a joint analysis of datasets on rheumatoid arthritis and coeliac disease also indicated a role of ANKRD55 in the latter. 6 Given the augmenting evidence suggesting an overlap in the genetic architecture of autoimmune diseases including MS, we have previously investigated 10 'autoimmune loci' in 2895 Spanish MS cases and 2942 controls. 2 In that study, rs6859219 emerged as a putative new MS locus albeit at subgenomewide significance ( p=1.9×10 −7 ). 2 Our failure to establish genome-wide significance was likely owing to the comparatively small sample size; thus, we set out to corroborate our initial association finding in additional independent datasets and to assess the overall evidence for association by meta-analysis.
We genotyped rs6859219 in 5106 MS cases and 3740 healthy control subjects of self-reported European descent from Germany and France 7 8 (table 1) using a commercially available assay ('TaqMan', Applied Biosystems, Inc.). Furthermore, we obtained, reanalysed and included data on 1868 cases and 3135 controls for rs6859219 from two publicly available GWAS ('IMSGC' 9 and 'GeneMSA'; 10 in the latter, rs6859219 was analysed following imputation). GWAS quality control, imputation and analysis protocols were followed as described previously. 8 Combined, these replication datasets comprised 6974 cases and 6875 controls and had ∼94% power to detect an OR of 1.20 at α=1×10 . Power to detect association at genomewide significance (α=5×10
) using all available data (9869 cases and 9817 controls, ie, after including the Spanish datasets of the original study) was ∼96%.
Genotyping efficiency and accuracy (based on 5% duplicate samples) in the newly genotyped datasets were 99.0% and 100%, respectively. Genotypes in controls were distributed according to Hardy-Weinberg equilibrium ( p=0.209 using Pearson's χ 2 ). Logistic regression analyses based on an additive model were adjusted for age and sex in the German and French datasets, and for principal components (PC 1-3) in IMSGC and GeneMSA to account for population substructure as previously described. 8 Fixed-effect meta-analysis revealed significant association of the ANKRD55 rs6859219 C-allele with increased risk for MS across all replication datasets (OR=1.15, 95% CI 1.08 to 1.23, p=1.0×10 −5 , figure 1) . Inclusion of the Spanish case-control datasets now exceeded the threshold for genome-wide significance by more than three orders of magnitude (OR=1.19, 95% CI 1.13 to 1.25, p=3.1×10 −11 , figure 1 ). While we found some evidence for heterogeneity of effect size estimates across datasets (I 2 =62, 95% CI 20 to 83, p Q statistic=0.0093; figure 1 ), all dataset-specific ORs suggested a risk effect for the C-allele, except for Central Spain. This indicates that heterogeneity was nearly entirely due to variance of effect size estimates at the same side of the null (OR<1).
Despite the compelling evidence now adding ANKRD55 to the list of established MS risk loci, the following limitations should be considered when interpreting our results. First, since determination of ethnic origin was based on self-report in the German, French and Spanish datasets, the possibility exists that results in these samples are affected by more subtle population substructure. However, appropriately adjusting for potential substructure effects in the GWAS datasets did not show any substantial change in results as compared with the unadjusted datasets. Hence, it is unlikely that population substructure has had a notable influence on our association results with rs6859219. Second, not all MS GWAS datasets published to date are publicly available and could therefore not all be included in the current study. This applies to two datasets in particular ('Australia and New Zealand Multiple Sclerosis Genetics Consortium' and 'Brigham and Women's Hospital') included in a recent GWAS meta-analysis that reported an association between rs6859219 and MS at nominal significance. 11 However, combining the summary results reported in that study 11 with our data (while excluding the GeneMSA and IMSGC results calculated here) does not appreciably change our overall meta-analysis results (OR=1.16, 95% CI 1.11 to 1.22, p=2.9×10 −10 ). Finally, the pathophysiological mechanisms underlying the association between rs6859219 in ANKRD55 and MS remain elusive. Rs6859219 is located in intron 7 of the gene, which is highly expressed in CD4 effector memory cells 12 but whose function remains largely unknown. As described previously, the linkage disequilibrium pattern (LD) around ANKRD55 is rather narrow, 2 5 and rs6859219 shows noteworthy LD (r 2 ≥0.3) only with other intronic ANKRD55 variants (based on 1000G CEU data; assessed with the SNAP software, http://www.broadinstitute.org/mpg/snap/). The LD block does not appear to extend to the two neighbouring genes (IL6ST encoding interleukin 6 signal transducer and IL31RA encoding interleukin 31 receptor A), which may be other immediate candidates interfering with the underlying autoimmune process in MS. Interestingly, recent in vitro ChIP-seq data generated by the (10) AAE, age at examination; AAO, age at onset; N, number. Figure 1 Meta-analysis of datasets assessing the association between ANKRD55 rs6859219 and multiple sclerosis susceptibility in populations of European descent. Study-specific ORs (black squares) and 95% CIs (lines) were calculated using an additive model. The x-axis depicts the OR with regard to the risk allele dosage, that is, the C-allele. The summary ORs and 95% CIs (grey diamonds) were calculated based on fixed-effect meta-analysis combining all datasets as well as after stratification for the initial datasets and the validation datasets as indicated. GeneMSA, Genetic Multiple Sclerosis Associations
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; GWAS, genome-wide association studies; IMSGC, International Multiple Sclerosis Genetics Consortium 9 ; RAF, risk allele frequency in controls in the individual datasets.
international ENCODE project indicate that rs6859219, located ∼182 kb 5 0 of the IL6ST transcription start site, lies within a target site for several transcription factors including activating enhancer binding protein 2 and early B cell factor 1 13 (accessible via http://genome.ucsc.edu/cgi-bin/hgGateway). Thus, functional genetic studies have to assess whether the association between rs6859219 and risk for MS and other autoimmune diseases is due to a dysfunction of ANKRD55, for example, via affecting mRNA splicing, or whether the effects may be caused by an altered transcriptional regulation ofIL6ST and/or IL31RA. Provenance and peer review Not commissioned; externally peer reviewed.
